Advances in Screening Technologies for Drug Discovery

Novalix is pleased to announce its participation as a speaker at Advances in Screening Technologies for Drug Discovery, a joint Societé de Chimie Therapeutique (SCT) and ChemBioFrance Meeting.

This Symposium will cover innovation and applied state-of-the-art screening technologies contributing to advance drug discovery boundaries. Selected themes of the Symposium will be dedicated to “breakthrough” discoveries or innovative technologies/methods, and will include DEL, mass spectrometry application or ultra large chemical spaces.

Mass Spectrometry (MS) in Drug Discovery: Challenges in non-covalent (Affinity-Selection MS) and covalent screening

Do not miss the lecture from Johann Stojko, PhD, Senior Project Manager, Biophysics, Mass Spectrometry, at 3 p.m.

Abstract: Mass spectrometry has emerged as a powerful tool in drug discovery, enabling identification and characterization of both non-covalent and covalent binders from in-solution and label free biomolecular targets and chemical libraries.
Affinity Selection Mass Spectrometry (ASMS) demonstrates its tremendous benefits in terms of throughput by its ability to screen in cocktails, hundreds of compounds simultaneously. Moreover, this binding site agnostic approach can be applied to a broad range of biomolecular targets including soluble or membrane proteins and their associated complexes. […]

Integrated screening and structural approaches for covalent and non-covalent hit discovery

Novalix will also contribute to the scientific program with a poster presentation from Christina Starck, Scientist in Mass Spectrometry.

Abstract: At Novalix, covalent fragment hits are identified using denaturing liquid chromatography and mass spectrometry-based screening, enabling direct detection and quantification of covalent adducts. Non-covalent lead-like hits are unveiled through affinity selection–mass spectrometry (AS-MS) and DNA-encoded library (DEL) screening, allowing rapid exploration of large chemical spaces and supporting high-throughput campaigns. Progression from hit identification to validation is achieved through orthogonal approaches providing insights into molecular mechanisms of action, binding affinity, specificity, selectivity, and SAR.[…]

Don’t miss these presentations!

If you are also attending, set a meeting and catch up. We look forward to meeting you there.